PharmaTimes -
December 2020

2020 will undoubtedly go down in history as being the year the world as we know it was crushed by a new coronavirus, thought to have emerged from Wuhan, China, last December. Just 11 months later, around 1.5 million people were recorded as having lost their lives to COVID-19, with millions more left struggling in its wake. Death, lockdown, isolation, furlough, redundancy, PPE, tiers, sanitiser, testing, R numbers and support bubbles are just some of the terms that will forever be synonymous with 2020, depicting a level of bleakness which no-one could have predicted.

However, the darkness also allowed some of the more laudable aspects of humanity to shine brighter, such as the collective recognition and celebration of healthcare workers as superheroes, the banding together of communities to protect their vulnerable, and the linking of academia and industry in a fervent race to find a vaccine, which now seems close to the finish line (see page 7).

Similarly, the healthcare and life sciences sectors quickly had to adapt to a seismic shift in operation necessitated by the pandemic, but this has also had the effect of vastly accelerating progress in certain areas that should ultimately benefit patients, as shown by some of the articles in our Review of the Year. For example, on page 13 John Pinching touches on how the coronavirus has jolted pharma into making digital a force for good, while the team at Wilmington outline how COVID-19 has jump-started the NHS Reset and brought forward changes laid out in the NHS Long Term Plan (p18). Jenny Ousbey also describes the impact of 2020 on the patient experience and how advocacy addressed new challenges (p26).

As 2020 draws to a close, it remains to be seen when the pandemic will end allowing life to begin a return to ‘normal’. However, with several vaccines in late-stage development, as well as a huge spectrum of other treatments designed to boost the chance of surviving COVID-19, it is my hope that this time next year we will find ourselves in an altogether more positive position.

I hope you enjoy the issue!

December 2020 - magazine highlights

Thumbnail image for The digital highway

The digital highway

Injecting the lightning bolt of digital into the relentless ambition of pharma has created a portal into the future, and not a moment too soon

Thumbnail image for A critical juncture

A critical juncture

Leslie Galloway looks back over 2020, outlining the challenges faced by the life sciences sector and the potential opportunities that lie ahead

Thumbnail image for Responding to the crisis

Responding to the crisis

Oli Hudson explores the changes that have occurred in the NHS this year as the Long Term Plan has been rolled out at speed in response to the COVID crisis

Thumbnail image for Movers and shakers

Movers and shakers

As mega deals slow, private capital becomes the driving force behind 2020 M&A

Thumbnail image for R&D trends

R&D trends

Accelerating innovation and its impact on patients and sites

Thumbnail image for SMART PEOPLE INSIGHT: Dr Jan Westerink

SMART PEOPLE INSIGHT: Dr Jan Westerink

A new, pooled analysis of data from Novo Nordisk’s Phase III trials SUSTAIN 6 and PIONEER 6 shows that semaglutide may help patients with type 2 diabetes live longer without a cardiovascular event. PharmaTimes talks to lead study investigator Dr Jan Westerink about the importance of these findings

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download